NASDAQ : PBLS
Parabilis Medicines, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 28.32 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.50B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 33.01M | 22.27M | 21.13M |
| Research & Development | 125.58M | 125.58M | 100.83M |
| Operating Expenses | 158.59M | 147.85M | 121.96M |
| Operating Income | -171.54M | -147.85M | -121.96M |
| Interest Expense | -1.23M | -1.52M | -1.49M |
| Interest & Investment Income | 7.70M | 3.39M | 6.41M |
| Other Non Operating Income (Expenses) | -5.46M | 98.00K | -877.00K |
| Pretax Income | -170.53M | -145.89M | -117.91M |
| Net Income | -170.53M | -145.89M | -117.91M |
| Preferred Dividends & Other Adjustments | 61.13M | 41.04M | 43.57M |
| Net Income to Common | -231.67M | -186.93M | -161.48M |
| Shares Outstanding (Basic) | 9.88M | 3.11M | 2.98M |
| Shares Outstanding (Diluted) | 9.88M | 3.11M | 2.98M |
| EPS (Basic) | -23.45 | -60.04 | -54.25 |
| EPS (Diluted) | -23.45 | -60.04 | -54.25 |
| Free Cash Flow | -112.49M | -124.02M | -104.49M |
| Free Cash Flow Per Share | -11.38 | -39.83 | -35.10 |
| EBITDA | -169.11M | -145.35M | -119.85M |
| D&A For EBITDA | 2.43M | 2.50M | 2.11M |
| EBIT | -171.54M | -147.85M | -121.96M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 1.09B | 27.71M | 47.28M |
| Short-Term Investments | 33.64M | 40.69M | |
| Cash & Short-Term Investments | 1.12B | 27.71M | 87.98M |
| Other Receivables | 1.76M | ||
| Receivables | 1.76M | ||
| Prepaid Expenses | 4.70M | 1.65M | 2.47M |
| Total Current Assets | 1.13B | 29.36M | 92.21M |
| Property, Plant & Equipment | 42.44M | 45.94M | 52.91M |
| Long-Term Deferred Charges | 600.00K | ||
| Other Long-Term Assets | 7.43M | 4.92M | 4.13M |
| Total Assets | 1.18B | 80.82M | 149.25M |
| Accounts Payable | 18.52M | 17.27M | 9.51M |
| Accrued Expenses | 14.35M | 17.41M | 12.90M |
| Current Portion of Long-Term Debt | 5.71M | 13.08M | 2.50M |
| Current Portion of Leases | 8.26M | 7.81M | 6.88M |
| Other Current Liabilities | 5.62M | 1.22M | 622.00K |
| Total Current Liabilities | 62.84M | 56.79M | 32.41M |
| Long-Term Debt | 12.79M | ||
| Long-Term Leases | 33.54M | 37.81M | 44.03M |
| Other Long-Term Liabilities | 2.74M | 3.58M | |
| Total Liabilities | 127.53M | 97.34M | 92.81M |
| Additional Paid-In Capital | 1.69B | 15.01M | 11.66M |
| Retained Earnings | -639.28M | -541.50M | -395.62M |
| Comprehensive Income & Other | -18.00K | 21.00K | |
| Total Common Equity | 1.05B | -526.50M | -383.94M |
| Shareholders' Equity | 1.05B | -16.52M | 56.44M |
| Total Liabilities & Equity | 1.18B | 80.82M | 149.25M |
| Total Debt | 47.51M | 58.70M | 66.20M |
| Net Cash (Debt) | 1.07B | -30.99M | 21.78M |
| Net Cash Per Share | 108.61 | -9.95 | 7.32 |
| Filing Date Shares Outstanding | 123.53M | 3.13M | 2.98M |
| Total Common Shares Outstanding | 123.52M | 3.13M | 2.98M |
| Working Capital | 1.06B | -27.43M | 59.80M |
| Book Value Per Share | 8.48 | -168.09 | -128.98 |
| Tangible Book Value | 1.05B | -526.50M | -383.94M |
| Tangible Book Value Per Share | 8.48 | -168.09 | -128.98 |
| Machinery | 12.80M | 11.93M | 11.91M |
| Leasehold Improvements | 4.69M | 4.56M | 4.50M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -170.53M | -145.89M | -117.91M |
| Depreciation & Amortization | 2.43M | 2.50M | 2.11M |
| Loss (Gain) From Sale of Assets | 360.00K | ||
| Loss (Gain) From Sale of Investments | 5.48M | 609.00K | -609.00K |
| Stock-Based Compensation | 6.58M | 3.32M | 4.31M |
| Other Operating Activities | 6.89M | 6.63M | 7.22M |
| Change in Accounts Payable | 6.85M | 13.59M | 9.28M |
| Change in Other Net Operating Assets | -10.50M | -4.47M | -8.37M |
| Operating Cash Flow | -111.29M | -123.71M | -103.61M |
| Capital Expenditures | -1.20M | -306.00K | -879.00K |
| Investment in Securities | -24.67M | 40.06M | 31.12M |
| Investing Cash Flow | -25.87M | 39.76M | 30.24M |
| Long-Term Debt Repaid | -3.08M | ||
| Net Debt Issued (Repaid) | -10.61M | -3.08M | |
| Issuance of Common Stock | 802.37M | 34.00K | 1.07M |
| Other Financing Activities | 46.88M | -17.00K | |
| Financing Cash Flow | 1.14B | 64.38M | 78.07M |
| Net Cash Flow | 1.01B | -19.57M | 4.70M |
| Free Cash Flow | -112.49M | -124.02M | -104.49M |
| Free Cash Flow Per Share | -11.38 | -39.83 | -35.10 |
| Levered Free Cash Flow | -72.40M | ||
| Unlevered Free Cash Flow | -71.44M | ||
| Cash Interest Paid | 1.03M | 1.25M | 1.03M |
| Change in Working Capital | 37.86M | 9.12M | 910.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 3.50B | ||
| Enterprise Value | 2.43B | ||
| Debt / Equity Ratio | 0.04 | -3.55 | 1.17 |
| Net Debt / Equity Ratio | -1.02 | -1.88 | -0.39 |
| Net Debt / EBITDA Ratio | 6.35 | -0.21 | 0.18 |
| Net Debt / FCF Ratio | 9.54 | -0.25 | 0.21 |
| Quick Ratio | 17.83 | 0.49 | 2.77 |
| Current Ratio | 17.91 | 0.52 | 2.85 |
| Return on Equity (ROE) | -731.00% | ||
| Return on Assets (ROA) | -80.33% | ||
| Return on Capital Employed (ROCE) | -15.40% | -615.30% | -104.40% |
| Buyback Yield / Dilution | -4.59% |